Comparison of DNA and RNA substrate effects on TET2 structure

被引:6
|
作者
Leddin, Emmett M. [1 ]
Cisneros, G. Andres [1 ]
机构
[1] Univ North Texas, Dept Chem, Denton, TX 76203 USA
来源
NON-HEME IRON ENZYMES - STRUCTURES AND MECHANISMS | 2019年 / 117卷
关键词
MOLECULAR-DYNAMICS SIMULATIONS; FIDELITY CHECKING; INSIGHT; ENZYMES; 5-FORMYLCYTOSINE; METHYLATION; MECHANISM; OXIDATION; CHARGES; AMBER;
D O I
10.1016/bs.apcsb.2019.05.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Ten-eleven translocation (TET) enzymes can perform the stepwise oxidation of 5-methylcytosine (5mC) to 5-carboxylcytosine on both single-stranded (ss) and double-stranded (ds) DNA and RNA. It has been established that TET2 has a preference for ds DNA substrates, but it can catalyze the oxidation reaction on both ssDNA and RNA. The reasons for this substrate preference have been investigated for only a substrate 5mC ribonucleotide in a DNA strand, but not other nucleic acid configurations (Biochemistry 58 (2019) 411). We performed molecular dynamics simulations on TET2 with various ss and ds substrates in order to better understand the structural and dynamical reasons for TET2's preference to act on ds DNA. Our simulations show that substrates that have a ribonucleotide experience several disruptions in their overall backbone shape, hydrogen bonding character, and nonebonded interactions. These differences appear to lead to the instability of ribonucleotide in the active site, and provide further rational for TET2's experimental behavior.
引用
收藏
页码:91 / 112
页数:22
相关论文
共 50 条
  • [31] TET2 mutations in childhood leukemia
    Langemeijer, S. M. C.
    Jansen, J. H.
    Hooijer, J.
    van Hoogen, P.
    Stevens-Linders, E.
    Massop, M.
    Waanders, E.
    van Reijmersdal, S. V.
    Stevens-Kroef, M. J. P. L.
    Zwaan, C. M.
    van den Heuvel-Eibrink, M. M.
    Sonneveld, E.
    Hoogerbrugge, P. M.
    van Kessel, A. Geurts
    Kuiper, R. P.
    LEUKEMIA, 2011, 25 (01) : 189 - 192
  • [32] Mutation in TET2 in Myeloid Cancers
    Delhommeau, Francois
    Dupont, Sabrina
    Della Valle, Veronique
    James, Chloe
    Trannoy, Severine
    Masse, Aline
    Kosmider, Olivier
    Le Couedic, Jean-Pierre
    Robert, Fabienne
    Alberdi, Antonio
    Lecluse, Yann
    Plo, Isabelle
    Dreyfus, Francois J.
    Marzac, Christophe
    Casadevall, Nicole
    Lacombe, Catherine
    Romana, Serge P.
    Dessen, Philippe
    Soulier, Jean
    Viguie, Franck
    Fontenay, Michaela
    Vainchenker, William
    Bernard, Olivier A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (22): : 2289 - 2301
  • [33] TET2: the fat controller of leptin
    Callen C.Goldsmith
    Garron T.Dodd
    Life Metabolism, 2024, 3 (04) : 14 - 16
  • [34] TET2 mutations in childhood leukemia
    S M C Langemeijer
    J H Jansen
    J Hooijer
    P van Hoogen
    E Stevens-Linders
    M Massop
    E Waanders
    S V van Reijmersdal
    M J P L Stevens-Kroef
    C M Zwaan
    M M van den Heuvel-Eibrink
    E Sonneveld
    P M Hoogerbrugge
    A Geurts van Kessel
    R P Kuiper
    Leukemia, 2011, 25 : 189 - 192
  • [35] The Role of TET2 in Hematologic Neoplasms
    Holmfeldt, Linda
    Mullighan, Charles G.
    CANCER CELL, 2011, 20 (01) : 1 - 2
  • [36] TET2: the fat controller of leptin
    Goldsmith, Callen C.
    Dodd, Garron T.
    LIFE METABOLISM, 2024, 3 (04):
  • [37] TET2: epigenetic safeguard for HSC
    Ko, Myunggon
    Rao, Anjana
    BLOOD, 2011, 118 (17) : 4501 - 4503
  • [38] TET2 in Normal and Malignant Hematopoiesis
    Bowman, Robert L.
    Levine, Ross L.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (08):
  • [39] Prevalence of TET2 mutations in MDS
    Kosmider, O.
    Gelsi-Boyer, V.
    Cheok, M.
    Grabar, S.
    Guardiola, P.
    Beyne-Rauzy, O.
    Quesnel, B.
    Solary, E.
    Vey, N.
    Hunault-Berger, M.
    Fenaux, P.
    Mansat-de Mas, V.
    Guesnu, M.
    Viguie, F.
    Lacombe, C.
    Vainchenker, W.
    Preudhomme, C.
    Birnbaum, D.
    Dreyfus, E.
    Bernard, O.
    Fontenay, M.
    LEUKEMIA RESEARCH, 2009, 33 : S43 - S44
  • [40] Dysregulation of TET2 in hematologic malignancies
    Chiba, Shigeru
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (01) : 17 - 22